Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0X9PF
|
|||
| Former ID |
DCL000074
|
|||
| Drug Name |
Bremelanotide
|
|||
| Synonyms |
Bremelanotide (USAN/INN); PT-141; Rekynda
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Hypoactive sexual desire dysfunction [ICD-11: HA00; ICD-10: F52.0] | Approved | [1] | |
| Erectile dysfunction [ICD-11: HA01.1; ICD-10: N48.4; ICD-9: 302.72, 607.84] | Phase 3 | [2] | ||
| Company |
Palatin Technol
|
|||
| Structure |
 |
Download2D MOL
|
||
| Formula |
C50H68N14O10
|
|||
| Canonical SMILES |
CCCCC(C(=O)NC1CC(=O)NCCCCC(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC1=O)CC2=CN=CN2)CC3=CC=CC=C3)CCCN=C(N)N)CC4=CNC5=CC=CC=C54)C(=O)O)NC(=O)C
|
|||
| InChI |
1S/C50H68N14O10/c1-3-4-16-35(58-29(2)65)43(67)64-41-25-42(66)54-20-11-10-18-37(49(73)74)60-46(70)39(23-31-26-56-34-17-9-8-15-33(31)34)62-44(68)36(19-12-21-55-50(51)52)59-45(69)38(22-30-13-6-5-7-14-30)61-47(71)40(63-48(41)72)24-32-27-53-28-57-32/h5-9,13-15,17,26-28,35-41,56H,3-4,10-12,16,18-25H2,1-2H3,(H,53,57)(H,54,66)(H,58,65)(H,59,69)(H,60,70)(H,61,71)(H,62,68)(H,63,72)(H,64,67)(H,73,74)(H4,51,52,55)/t35-,36-,37-,38+,39-,40-,41-/m0/s1
|
|||
| InChIKey |
FFHBJDQSGDNCIV-MFVUMRCOSA-N
|
|||
| CAS Number |
CAS 189691-06-3
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Melanocortin receptor 1 (MC1R) | Target Info | Agonist | [1] |
| Melanocortin receptor 4 (MC4R) | Target Info | Agonist | [1] | |
| KEGG Pathway | Neuroactive ligand-receptor interaction | |||
| Melanogenesis | ||||
| Pathway Interaction Database | Syndecan-3-mediated signaling events | |||
| Reactome | Peptide ligand-binding receptors | |||
| G alpha (s) signalling events | ||||
| WikiPathways | GPCRs, Class A Rhodopsin-like | |||
| Peptide GPCRs | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019 | |||
| REF 2 | Designing drugs for the treatment of female sexual dysfunction. Drug Discov Today. 2007 Sep;12(17-18):757-66. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.